Proposed Rules Against Discriminatory Practices for 340B Pharmacies…

The Frame

What this does

This bill would establish new legal standards for how 340B-covered entities are reimbursed for drugs, potentially impacting the operational costs and revenue models for hospitals and clinics participating in the federal 340B drug pricing program.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

340B Entities

These entities would be subject to new protections regarding how they are reimbursed for drugs and how they receive drug shipments.

Drug Manufacturers

Manufacturers would be prohibited from engaging in specific practices related to the delivery and acquisition of 340B drugs.

Pharmacy Benefit Managers (PBMs)

PBMs would be prohibited from applying discriminatory reimbursement rates to 340B entities.

Health Insurers

Insurers and HMOs would be prohibited from engaging in discriminatory reimbursement practices toward 340B entities.

What changed

Last recorded activity March 13, 2026.

What's next

Introduced.

Summary

Senate Bill 1638 proposes new regulations to prevent drug manufacturers, health insurers, and pharmacy benefit managers from discriminating against . The bill specifically targets how these drugs are acquired, delivered, and reimbursed.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Why It Matters

This bill would establish new legal standards for how 340B-covered entities are reimbursed for drugs, potentially impacting the operational costs and revenue models for hospitals and clinics participating in the federal 340B drug pricing program.

Frequently Asked Questions

What is the 340B program?

The 340B program is a federal government program that requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations at significantly reduced prices.

Who does this bill regulate?

The bill regulates drug manufacturers, health insurance issuers, , and other .